Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about recent paper Jorge E. Cortes and colleagues authored:
“Final results are in from a Phase 1 trial combining asciminib (the first STAMP inhibitor) with ATP-competitive TKIs in chronic or accelerated phase CML.
Asciminib targets the ABL myristoyl pocket, and in preclinical models, it synergized with TKIs like nilotinib, imatinib, and dasatinib to overcome resistance and prevent relapse.
Key findings from the 3 combination arms:
– Rapid efficacy
– Decreased tolerability vs. asciminib alone
Recommended doses:
- Asciminib 40 mg BID + Nilotinib 300 mg BID
- Asciminib 40/60 mg QD + Imatinib 400 mg QD
- Asciminib 80 mg QD + Dasatinib 100 mg QD
Max tolerated dose was reached with asciminib + imatinib, but not with the other combos.
Bottom line: Combination therapy shows promise for patients with suboptimal responses to TKI monotherapy, but safety/tolerability balance is key.”
Authors: Jorge E. Cortes et al.
